IPO - Lantern Pharma Inc.

Form Type: 424B5

Filing Date: 2025-07-03

Corporate Action: Ipo

Type: New

Accession Number: 000164117225017790

Filing Summary: Lantern Pharma Inc. has filed a prospectus supplement in relation to its ongoing at-the-market (ATM) offering through an agreement with ThinkEquity LLC, allowing the company to sell shares of its common stock for an aggregate offering price of up to $15,530,000. The common stock is listed on the Nasdaq Capital Market under the symbol 'LTRN'. The offering will consist of common shares with a par value of $0.0001, based on the last reported sales price of $3.18 per share. The funds raised will be utilized for working capital and general corporate purposes. This strategic move comes as part of Lantern Pharma's plan to expand its operations focused on developing cancer therapies utilizing its AI platform, RADR®, aiming to expedite drug discovery and development processes. As of June 2025, the public float was valued at approximately $46.6 million. The company emphasized that investments in its securities carry a high degree of risk and underscored the importance of reviewing the associated risk factors prior to investment decisions.